IDEXX Laboratories: Growth Remains Despite Weak Clinical Visits

Core Viewpoint - IDEXX Laboratories, Inc. (NASDAQ: IDXX) has seen a stock price increase of over 22% since being upgraded to a Buy rating in March 2025, despite a decline in U.S. clinical visits [1]. Company Performance - The company delivered strong quarterly results, indicating resilience in its operations despite external challenges [1]. Investment Strategy - The investment approach focuses on fundamental, bottom-up analysis with an emphasis on long-term quality growth, targeting companies in niche markets with strong growth potential and reasonable valuations [1]. - The portfolio typically consists of 15-20 stocks, emphasizing diversification, risk management, macro-driven sector weights, and disciplined trading [1].